<DOC>
	<DOCNO>NCT00719264</DOCNO>
	<brief_summary>To estimate difference efficacy safety bevacizumab RAD001 compare bevacizumab interferon alfa-2a first-line treatment patient metastatic carcinoma kidney .</brief_summary>
	<brief_title>Safety Efficacy Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Bevacizumab First-line Treatment Adult Patients With Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients metastatic renal cell carcinoma 2 . Patients least one measurable lesion 3 . Patients progressive metastatic renal cell carcinoma 4 . Patients prior partial complete nephrectomy 5 . Patients Karnofsky Performance Status ≥70 % . 6 . Adequate bone marrow function 7 . Adequate liver function 8 . Adequate renal function 9 . Adequate coagulation profile 1 . 4 week postmajor surgery 2 . Patients radiation therapy within 28 day prior start study 3 . Patients need major surgical procedure course study . 4 . Patients serious nonhealing wound , ulcer , bone fracture . 5 . Patients history seizure ( ) control standard medical therapy . 6 . Patients receive prior systemic treatment metastatic RCC . 7 . Patients receive prior therapy VEGF pathway inhibitor 8 . Patients previously receive systemic mTOR inhibitor 9 . Patients know hypersensitivity RAD001 ( everolimus ) rapamycins excipients . 10 . Patients history current central nervous system ( CNS ) metastases spinal cord compression . 11 . Patients history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment . 12 . Patients proteinuria screen . 13 . Patients inadequately control hypertension 14 . Patients receive ongoing recent need full therapeutic dose oral parenteral anticoagulant chronic daily treatment aspirin 15 . Patients receive chronic systemic treatment corticosteroid another immunosuppressive agent . 16 . Patients known history HIV 17 . Patients hypersensitivity interferon alfa2a component product . 18 . Patients active , bleed diathesis coagulopathy recurrent thromboembolism 19 . Patients severe and/or uncontrolled medical condition condition 20 . Left Ventricular Ejection Fraction &lt; low limit institutional normal assess ECHO MUGA 21 . Patients history another primary malignancy ≤ 3 year 22 . Female patient pregnant breast feed 23 . Patients use investigational agent receive investigational drug ≤ 4 week prior study treatment start . 24 . Patients unwilling unable comply protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Adults</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>RAD001</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Interferon</keyword>
	<keyword>Clear</keyword>
	<keyword>Roferon</keyword>
	<keyword>Avastin</keyword>
	<keyword>Nephrectomy</keyword>
	<keyword>newly diagnose</keyword>
</DOC>